AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Show more
Location: 150 West 4th Ave, Vancouver, BC, V5Y 1G6, Canada | Website: https://www.abcellera.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.197B
52 Wk Range
$1.89 - $4.33
Previous Close
$4.25
Open
$4.26
Volume
5,621,146
Day Range
$4.00 - $4.27
Enterprise Value
486.4M
Cash
605.3M
Avg Qtr Burn
-19.6M
Insider Ownership
22.97%
Institutional Own.
44.79%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bebtelovimab (LY-CoV1404) Details COVID-19 | Approved Update | |
Bamlanivimab (LY-CoV555) Details COVID-19 | Approved Quarterly sales | |
ABCL575 Details Moderate-to-severe atopic dermatitis (AD) | Phase 1 Initiation |